10:29 AM EDT, 10/10/2024 (MT Newswires) -- Palisade Bio ( PALI ) said Thursday it has received clearance from Health Canada to start a phase 1 trial that will evaluate PALI-2108 for the treatment of ulcerative colitis.
Preparations for the trial are ongoing and Palisade is on track to begin enrollment before the end of the year, the company said.
Price: 3.31, Change: -0.01, Percent Change: -0.45